- Home
- MCBS vs ABUS Comparison
MCBS vs ABUS Comparison
Compare MCBS & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCBS
- ABUS
- Stock Information
- Founded
- MCBS 2006
- ABUS 2005
- Country
- MCBS United States
- ABUS United States
- Employees
- MCBS N/A
- ABUS N/A
- Industry
- MCBS Major Banks
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- MCBS Finance
- ABUS Health Care
- Exchange
- MCBS Nasdaq
- ABUS Nasdaq
- Market Cap
- MCBS 709.2M
- ABUS 611.0M
- IPO Year
- MCBS 2019
- ABUS N/A
- Fundamental
- Price
- MCBS $29.35
- ABUS $3.13
- Analyst Decision
- MCBS Hold
- ABUS Strong Buy
- Analyst Count
- MCBS 1
- ABUS 4
- Target Price
- MCBS $34.00
- ABUS $5.50
- AVG Volume (30 Days)
- MCBS 50.1K
- ABUS 914.3K
- Earning Date
- MCBS 07-22-2025
- ABUS 07-31-2025
- Dividend Yield
- MCBS 3.07%
- ABUS N/A
- EPS Growth
- MCBS 30.91
- ABUS N/A
- EPS
- MCBS 2.58
- ABUS N/A
- Revenue
- MCBS $143,775,000.00
- ABUS $6,403,000.00
- Revenue This Year
- MCBS $16.00
- ABUS $3.35
- Revenue Next Year
- MCBS $31.75
- ABUS N/A
- P/E Ratio
- MCBS $11.28
- ABUS N/A
- Revenue Growth
- MCBS 19.70
- ABUS N/A
- 52 Week Low
- MCBS $24.24
- ABUS $2.71
- 52 Week High
- MCBS $36.15
- ABUS $4.73
- Technical
- Relative Strength Index (RSI)
- MCBS 57.73
- ABUS 41.34
- Support Level
- MCBS $29.64
- ABUS $3.11
- Resistance Level
- MCBS $30.13
- ABUS $3.36
- Average True Range (ATR)
- MCBS 0.59
- ABUS 0.13
- MACD
- MCBS 0.14
- ABUS -0.01
- Stochastic Oscillator
- MCBS 68.95
- ABUS 19.78
About MCBS MetroCity Bankshares Inc.
MetroCity Bankshares Inc is a holding company of its subsidiary Metro City Bank. It provides commercial banking services such as consumer and commercial checking accounts, savings accounts, certificates of deposits, commercial and consumer loans, money transfers and a variety of other banking services. The banks generate revenue from interest income. Its customers include small business owners, professionals, consumers, and real estate developers.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.